What are the recommended indications, dosing regimens, preparation steps, and contraindications for radioactive iodine (RAI) therapy in Filipino patients with differentiated thyroid carcinoma?

Guidelines for RAI in Filipinos with Thyroid Cancer

For Filipino patients with differentiated thyroid carcinoma, RAI therapy should follow the same evidence-based risk stratification approach used internationally, with no ethnic-specific modifications required. The most recent 2025 ATA guidelines 1 and 2025 NCCN guidelines 2 provide the contemporary framework for RAI decision-making.

Risk-Based Indications for RAI

Low-Risk DTC (T1a-T1b, N0)

• RAI is NOT recommended for tumors ≤1 cm that are intrathyroidal with no lymph node metastases 3
• For tumors 1-2 cm (T1b) without adverse features, RAI can be safely omitted 1
• Recent evidence from ESTIMABL2 and IoN trials confirms that thyroidectomy alone with surveillance is sufficient for low-risk disease 4

Critical caveat: If postoperative thyroglobulin (Tg) is 1-10 ng/mL or Tg antibodies are positive, consider RAI as 1.3-1.6% of distant metastases may be initially missed without it 5

Intermediate-Risk DTC

• RAI should be considered with activities ranging from 30 mCi (1.1 GBq) to 100 mCi (3.7 GBq) 3
• Decision factors include:
  • Extent of lymph node involvement
  • Extrathyroidal extension
  • Vascular invasion
  • Aggressive histologic variants
  • Postoperative Tg levels >10 ng/mL 5

High-Risk DTC (Gross extrathyroidal extension, distant metastases)

• RAI is strongly recommended at 100 mCi (3.7 GBq) or higher 3
• For known metastatic disease, activities of 100-200 mCi (3.7-7.4 GBq) are justified 6
• Lesional dosimetry may guide higher activities when needed 1

Dosing Regimens

Standard Activities by Risk Category:

• Remnant ablation (low-risk): 30 mCi (1.1 GBq) 3, 6
• Adjuvant therapy (intermediate-risk): 30-100 mCi (1.1-3.7 GBq) 3, 6
• Treatment of metastases: ≥100 mCi (3.7 GBq), up to 200 mCi (7.4 GBq) 6

Important: Cumulative RAI doses exceeding 1000 mCi (37 GBq) increase risk of secondary primary malignancies and should be avoided when possible 6

Preparation Steps

TSH Stimulation (Two Options):

Option 1: Recombinant Human TSH (rhTSH)

• Advantages: No hypothyroid symptoms, lower whole-body radiation exposure, better quality of life 7
• Appropriate for remnant ablation in low-intermediate risk patients 3
• Preferred for most ablation scenarios 1

Option 2: Thyroid Hormone Withdrawal

• Stop levothyroxine for 3-4 weeks to achieve TSH >30 mIU/L 7
• Required for patients with known metastatic disease as it provides higher sensitivity for detecting iodine-avid lesions 8
• Necessary when higher RAI uptake is needed for therapeutic effect

Low-Iodine Diet:

• Implement for 2-3 weeks prior to RAI administration 9, 8
• Enhances RAI uptake by depleting body iodine stores

Pre-Treatment Diagnostic Scanning:

• If performing pre-therapeutic dosimetry, limit diagnostic I-131 to 1-10 MBq to avoid stunning 8
• Consider I-123 or I-124 as alternative tracers 8

Contraindications

Absolute:

• Pregnancy (verify negative pregnancy test before RAI)
• Breastfeeding

Relative:

• Severe renal insufficiency (impairs RAI clearance)
• Inability to comply with radiation safety precautions
• Severe xerostomia or salivary gland dysfunction from prior RAI

Post-RAI Precautions

Reproductive Planning:

• Women: Avoid pregnancy for 6-12 months after RAI 9
• Men: Consider sperm banking before high-dose RAI; avoid conception for 4-6 months 9

Salivary Gland Protection:

• Encourage hydration and sialagogues (lemon candies, gum) starting 24 hours after RAI 8
• Maintain excellent dental hygiene to prevent caries from xerostomia 8

RAI-Refractory Disease

For clinically progressive or symptomatic RAI-refractory DTC, systemic therapy with kinase inhibitors should be considered 2. Lenvatinib is the preferred first-line agent based on phase III data showing clinical benefit in 50-60% of patients for 12-24 months 2. Traditional cytotoxic chemotherapy like doxorubicin has minimal efficacy and is not recommended 2.

Key Pitfalls to Avoid

1. Over-treating low-risk disease: The pendulum has shifted away from routine RAI in tumors ≤1 cm 10, 4
2. Ignoring postoperative Tg levels: Tg 1-10 ng/mL or positive Tg-abs warrant closer consideration of RAI even in otherwise low-risk patients 5
3. Excessive cumulative RAI: Monitor lifetime cumulative dose; consider alternative therapies before exceeding 1000 mCi 6
4. Using rhTSH for metastatic disease: Endogenous TSH stimulation via withdrawal is superior for treating known metastases 8, 7